Potential Therapeutic Targets in Uterine Sarcomas

Area of Science:

• Gynecologic Oncology
• Molecular Oncology
• Translational Medicine

Background:

• Uterine sarcomas are rare, aggressive cancers with poor outcomes and limited treatment options.
• High rates of relapse and distant metastasis necessitate novel therapeutic strategies beyond conventional cytotoxic treatments.
• Understanding the molecular heterogeneity of uterine sarcoma subtypes is crucial for developing targeted therapies.

Purpose of the Study:

• To review emerging molecular targets for four distinct uterine sarcoma subtypes.
• To summarize promising targeted therapy approaches based on clinical and preclinical data.
• To highlight the need for personalized treatment strategies in uterine sarcoma management.

Main Methods:

• Literature review of clinical reports and preclinical studies on uterine sarcoma treatment.
• Identification and categorization of potential molecular targets within specific uterine sarcoma subtypes.
• Analysis of current and investigational therapeutic strategies, including targeted therapies and antihormonal treatments.

Main Results:

• For uterine leiomyosarcoma, targeting VEGF and mTOR signaling, alongside approved therapies like pazopanib, shows promise. Preclinical data support targeting histone deacetylases, tyrosine kinase receptors, and aurora kinase A.
• Low-grade endometrial stromal sarcomas demonstrate activity with antihormonal therapies (aromatase inhibitors, progestins), with potential targets including PDGFR, VEGFR, and histone deacetylases.
• High-grade endometrial stromal sarcomas with the YWHAE/FAM22A/B fusion gene may respond to targeting the 14-3-3 oncoprotein, c-KIT, or the Wnt pathway.

Conclusions:

• Uterine sarcoma subtypes exhibit distinct molecular profiles, requiring tailored therapeutic approaches.
• Targeted therapies inhibiting specific signaling pathways and oncoproteins represent a promising avenue for improving patient outcomes.
• Personalized medicine, considering the molecular heterogeneity of uterine sarcomas, is essential for advancing treatment efficacy.